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A systematic study on generating simian immunodeficiency virus (SIV)-based vectors was carried out. The goal was to
generate helper-free, replication-defective SIVmac-based vectors at high titers. The general approach was to cotransfect into
human 293T cells a plasmid carrying the vector construct along with two helper plasmids that together expressed the
SIVmac virion proteins. Initial vectors carried the bacterial b-galactosidase gene (b-gal). These vectors had a technical
difficulty: “pseudotransduction” of b-gal protein produced during the 293T cell transfections. As a result, infection of cultures
with these vector stocks also resulted in passive transfer into, and X-gal staining of, cells that had not actually been infected
by the vector. A second generation of vectors expressing the enhanced jellyfish green fluorescence protein (EGFP) was not
subject to this artifact. A systematic study of the SIVmac-based EGFP vectors was carried out. Helper-free vector stocks
were obtained when helper plasmids lacking the SIVmac packaging signals were used. By employing envelope helper
plasmids derived from different SIVmac isolates, it was possible to generate SIVmac-based vectors pseudotyped with
envelope proteins of different cell tropism. Optimization of vector and helper plasmid structures, transfection conditions, and
infection procedures ultimately yielded vector titers in excess of 106/ml. © 2001 Academic PressINTRODUCTION
Retrovirus-based vectors have been of interest from
the point of gene therapy, as well as for studies on
retrovirus biology. Initially, vectors based on the simple
retroviruses such as murine leukemia virus and spleen
necrosis virus received the most attention (Cepko et al.,
1984; Hwang and Gilboa, 1984; Rubenstein et al., 1984;
Sorge et al., 1984; Stuhlmann et al., 1984; Williams et al.,
1984). More recently, vectors based on HIV have been
developed (Buchschacher and Panganiban, 1992; Kal-
pana, 1999; Shimada et al., 1991; Zufferey et al., 1998).
These latter vectors have the potential advantage of
infecting resting cells, due to the fact that accessory and
viral structural genes in lentiviruses such as HIV allow
infection of resting cells (MA and vpr) (Bukrinsky et al.,
1993; Gallay et al., 1995; Heinzinger et al., 1994; Rey et al.,
1998; von Schwedler et al., 1994). On the other hand,
generation of lentivirus-based vectors has been chal-
lenging because certain viral proteins (e.g., envelope)
are toxic to cells, and other proteins (vpr) cause growth
arrest (Emerman, 1996; Jowett et al., 1995; Levy et al.,
1994; Poon et al., 1998; Rogel et al., 1995). As a result, it
has been difficult to generate efficient packaging cell
lines for lentiviral vectors. It has also been difficult to
1 To whom reprint requests should be addressed. Fax: (949) 824-
023. E-mail: hyfan@uci.edu.
0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
154generate high-titer HIV-based vector stocks, unless
pseudotypes with the VSV G protein are prepared (Ak-
kina et al., 1996; Chang et al., 1999; Kafri et al., 1999; Li et
al., 1998; Mochizuki et al., 1998).
We have been interested in generating vectors based
on simian immunodeficiency virus (SIV). Such vectors
should be analogous to those based on HIV-1; our inter-
est has been driven by a desire to study early events
during infection in vivo. In a small animal model, we have
been able to observe in vivo infection with helper-free
replication-defective M-MuLV-based vectors in mice
(Okimoto and Fan, 1999). This has allowed us to identify
the first cells that are infected in vivo by M-MuLV, since
these vectors cannot spread infection to other cells. We
are interested in carrying out equivalent experiments
with SIV-based vectors in monkeys, since this could
allow identification of the cellular pathway of infection
after different routes of viral exposure. As indicated
above, the major challenges were likely to involve devel-
oping systems where high titers of helper-free vector
could be obtained. Other investigators have described
generation of some SIV-based vectors (Gundlach et al.,
1997; Kirchhoff et al., 1997). In this report, we describe
generation of helper-free, replication-defective vectors
based on SIVmac. A systematic comparison of different
vector constructs as well as helper plasmids led to
production of the desired vectors at high titers, and






















The goal of these experiments was to generate helper-
ree SIV-based retroviral vectors. In particular, we wished
o generate high-titer stocks of vectors expressing
eadily identifiable reporter genes for use in in vivo in-
ections. Two reporter genes were considered: bacterial
b-galactosidase (b-gal), and the enhanced jellyfish
reen fluorescence protein (EGFP). Cells expressing ei-
her of these proteins can be readily identified by color-
metric or fluorescent stains (b-gal) or by intrinsic fluo-
rescence (EGFP), and other retroviral vectors expressing
these proteins have been generated.
Vectors expressing b-gal. The first vectors expressed
FIG. 1. First generation vector system. Schematic diagrams of the
SIVmac239-based vectors NK1 and NK2, the gag-pol helper plasmid
pNK3 and the envelope helper plasmid pNK4. The open boxes between
the LTRs indicate the coding sequences for SIV proteins in the vectors
or plasmids. Shaded boxes indicate inserted reporter gene cassettes.
Deletions of gag-pol (Dgagpol) or packaging signals (Dc) are also
indicated. Some plasmids contain the CMV immediate early promoter
or a bovine growth hormone polyadenylation (poly(A)) sequence. (A)
NK1 contains a 3.6-kb deletion in gag-pol which is replaced with an
RES-b-gal cassette. (B) NK2 contains the same 3.6-kb deletion in
gag-pol as NK1 and contains the IRES-b-gal cassette in the second
exon of rev. (C) pNK3 contains the SIV 59LTR driving expression of gag,
ol, vif, vpr, and vpx and contains the bovine growth hormone poly(A)
ignal. (D) pNK4 contains the CMV immediate early promoter driving
xpression of env, tat, and rev and contains the bovine growth hormone
oly(A) signal.b-gal as the reporter gene, downstream from an inter-
al ribosomal entry site (IRES), as diagrammed in Fig.. For NK1, the IRES-b-gal cassette was placed within
the gag-pol region; for this vector, expression of b-gal
would be from a “late” viral mRNA. NK2 contained the
IRES-b-gal cassette within the second exon of rev, so
expression of the reporter gene would be from an
“early” mRNA. To generate vector stocks, plasmids
containing these vector organizations (pNK1 and
pNK2, respectively) were cotransfected into 293T cells
with two helper plasmids that encoded SIV structural
proteins (pNK3 for gag-pol proteins and pNK4 for env
proteins). pNK3 and pNK4 were patterned after helper
plasmids designed by Parolin et al. for generation of
HIV-1-based vectors (Parolin et al., 1994). Superna-
tants from the cotransfected cells were used to infect
CEMX174 cells in the presence of 8 mg/ml DEAE–
dextran. As a negative control, supernatants from 293T
cells transfected with vector plasmid but no helper
plasmids were also “infected” into the CEMX174 cells.
Forty-eight hours postinfection, portions of the in-
fected cells were deposited onto glass slides by cy-
tocentrifugation, fixed with 4% paraformaldehyde,
stained for b-gal with X-gal, and scanned by light
microscopy for X-gal positive blue cells. Modest num-
bers of blue cells were detected in the infected
CEMX174 cells (Table 1). However, the control super-
natant from 293T cells transfected with vector plasmid
alone unexpectedly also showed blue cells when in-
fected onto the CEMX174 cells. This suggested that
some of the blue cells did not reflect genuine retroviral
vector infection. Indeed, treatment of the infected
CEMX174 cells with the reverse transcriptase inhibitor
TABLE 1
Pseudotransduction of b-Gala
Stock DEAE–dextranb AZTc Blue cellsd
1. pNK1 alone 1 2 96
. pNK1 alone 2 2 0
. NK1 2 2 3e
4. NK1 2 1 0
. NK1 1 2 91
. NK1 1 1 89
. b-Gal protein 2 2 0
. b-Gal protein 1 2 58
a Infection of 2 3 105 CEMX174 cells with viral vectors produced by
transfection of 293T cells with the b-gal-expressing vector plasmid
pNK1, the gag-pol helper plasmid pNK3, and the env helper plasmid
pNK4 (3–6). Results are also shown of mock infections with superna-
tant from 293T cells transfected with pNK1 alone (1 and 2) or with 500
ml of 1 mg/ml b-gal protein (7 and 8).
b Infections were performed in the presence or absence of 8 mg/ml
DEAE–dextran.
c Infections were performed in the presence or absence of 25 mM
AZT.
d Cells were fixed with 4% glutaraldehyde, X-gal stained at 48-h post-
infection and scored for blue cells.











156 KIM ET AL.AZT during infection did not abolish the appearance of
blue cells.
In other experiments, we found that infection of
CEMX174 cells in the absence of DEAE–dextran gave
blue cells only when supernatants from 293T cells co-
transfected with vector plasmid and the helper plasmids
were used; no blue cells were evident if supernatants
from 293T cells transfected with vector plasmid alone
were used (Table 1). Moreover, in the absence of DEAE–
dextran the appearance of blue cells was sensitive to
inhibition by AZT. The numbers of blue cells obtained
under these conditions were low (Table 1, line 3) but
reproducible in independent experiments. These low ti-
ters probably represented the fact that the NK1 vector
had an IRES near the 59 end of the genome (see below).
hese results suggested that there was genuine SIV-
ased vector in the cotransfected 293T cell superna-
ants, but that in the presence of DEAE–dextran, transfer
f b-gal was also occurring in the absence of infection.
Gallardo et al. have previously reported the phenom-
non of pseudotransduction, in which retroviral vector
tocks can incorporate proteins such as b-gal into the
viral particles and transfer the proteins into the infected
cells (Gallardo et al., 1997). It seemed quite likely that the
AZT-resistant blue cells in Table 1 represented some
TABLE 2
Infection with EGFP Vectorsa
Stocks DEAE–dextranb PMPAc EGFP(1) cellsd
1. pST1EGFP alone 1 2 0
2. ST1EGFP 2 2 350e
3. ST1EGFP 1 2 691
. ST1EGFP 1 1 0
. ST1EGFP heat 1 2 0
a Infection of 2 3 105 CEMX174 cells with viral vectors produced from
transfection of 293T cells with the EGFP-expressing vector pST1EGFP,
the gag-pol helper plasmid pUpSVODC and the env helper plasmid
pS-env (2–4). Results of mock infection with supernatant from transfec-
tion of pST1EGFP alone (1) or with heat-treated ST1EGFP vector su-
pernatant (5) are shown. Two microliters of each vector supernatant
was used in the infections.
b Infections were performed in the presence or absence of 8 mg/ml
DEAE–dextran.
c Infections were performed in the presence or absence of 100 mM
PMPA.
d Cells were scanned for green fluorescence 96-h postinfection.
e This number corresponds to a calculated titer of 1.17 3 105 GFU/ml.
FIG. 2. EGFP-containing vectors. Schematic diagrams of SIVmac239
in Fig. 1 are used. (A) ST1EGFP, (B) ST1.2EGFP, (C) ST3EGFP, (D) ST4EGF
contain two IRES-EGFP cassettes. (G) V1EGFP contains EGFP in place o
stop codons at the beginning of gag. In this diagram, deletions in env a
an open box. (H) V1IRES-EGFP is identical to V1EGFP except for an IR
are designated with the prefix “p” (e.g., pV1EGFP); in some cases, an SV40 ORI
sequences to facilitate amplification in 293T cells and is designated by an inform of pseudotransduction. To further explore the
source of the AZT-resistant b-gal signal in the infected
EMX174 cells, we measured supernatants from the
ransfected 293T cells for b-gal enzyme activity using the
ONPG assay. Significant levels of b-gal activity were
present in supernatants from 293T cells transfected with
vector plasmid alone, or cotransfected with vector plus
packaging plasmids (not shown). It thus seemed likely
that soluble b-gal in the 293T cell supernatants was
being taken up by the CEMX174 cells in the presence of
DEAE–dextran. Indeed, when we incubated CEMX174
cells with purified b-gal protein in the presence or ab-
sence of DEAE–dextran, blue cells resulted when the
incubations included DEAE–dextran (Table1).
While the results of Table 1 suggested that the
pseudotransduction artifact could be circumvented in
CEMX174 cells by omission of the DEAE–dextran during
infection, when primary rhesus macaque peripheral
blood-derived mononuclear cells (PBMCs) were ex-
posed to the transfected 293T cell supernatants, blue-
stained cells were evident in the absence of DEAE–
dextran regardless of whether helper plasmids had been
cotransfected. Thus, omission of DEAE–dextran did not
eliminate the pseudotransduction artifact in primary ma-
caque PBMCs.
SIV-based vectors expressing GFP. In light of the
pseudotransduction artifact discovered for the b-gal vec-
tors, we tested if a different reporter gene would prove
less problematic. A second generation of SIVmac-based
vector constructs was prepared that expressed the en-
hanced jellyfish GFP protein as described under Mate-
rials and Methods (Fig. 2). As an example, ST1EGFP is
equivalent to NK2 except that it expresses EGFP instead
of b-gal. Infection of CEMX174 cells with supernatant
from 293T cells transfected with pST1EGFPSVO cotrans-
fected with the helper plasmids showed EGFP-positive
cells 4 days postinfection (Table 2 and Fig. 3). Fluores-
cent cells were only evident when supernatant from 293T
cells cotransfected with the helper plasmids were used;
in addition, no EGFP-positive cells were detected when
infections were carried out in the presence of 100 mM
PMPA (another RT inhibitor). This suggested that the
EGFP signal in the infected cells resulted from genuine
retroviral infection and not through pseudotransduction.
The time of appearance of the EGFP signal in the in-
fected cells also supported the idea that this reflected
genuine infection. When portions of the infected cells
ning vectors utilizing EGFP as the reporter. The same conventions as
ontain a single IRES-EGFP cassette. (E) STX2EGFP and (F) ST3X2EGFP
nd is replication-defective due to a deletion in env and two consecutive
are indicated by shaded regions, and the inserted EGFP is shown as





has been placed on the vector (or helper) plasmid outside of the vector




158 KIM ET AL.were examined for green fluorescence at different times
postinfection, EGFP signal was not evident at 24 and
48 h postinfection. At 72 h, cells with low-level EGFP
expression were detected, while at 96 h bright green
cells with high-level EGFP were found. This time course
also suggests that the GFP detected in the infected cells
resulted from de novo synthesis and not from pseudo-
transduction of EGFP.
As another test, we treated vector-containing super-
natants with conditions that would inactivate retroviral
particles, but that would not disrupt contaminating plas-
mid DNA. Vector supernatants were heat treated at 65°C
for 1 h and then subjected to two cycles of freeze thaw-
ing. Infection of such treated supernatants onto
CEMX174 cells yielded no fluorescent cells (Table 2).
Taken together, these results indicate that GFP is a
suitable reporter gene for SIV-based vectors prepared by
the cotransfection method.
Vector parameters affecting efficiency of expression.
We prepared different SIVmac-based vectors expressing
EGFP and compared their efficiencies in producing high-
titer vector stocks. The organizations of these vectors are
shown in Fig. 2 also. In each case, vector stocks were
generated by cotransfecting 293T cells with a plasmid
FIG. 3. Infection of CMMT-CD4 cells with the V1EGFP vector. Fluo
1EGFP vector produced by 293T cotransfection of pV1EGFPSVO, pUpS
field as (A) under both fluorescent illumination and visible light. Note
(A) and (B) under light microscopy only. (D) Fluorescent microscopy of un
(E) Same field as (D) under both fluorescent and visible illumination. (version of the vector along with a gag-pol expression
plasmid and an envelope expression plasmid. For theseexperiments, the gag-pol expression plasmid was
pUpSVODC and the env expression plasmid was pS-env
(see below). Each vector stock was titered by infection
on CMMT-CD4 cells in the presence of 1.8 mg/ml DEAE–
dextran (Table 3). Two sets of the vectors were prepared;
within each set, all vectors were prepared at the same
time. Each set of vectors was also titered twice; for each
titration, all vectors in the set were assayed at the same
time. In Table 3, data from all of the titrations are pre-
sented. Since there was generally good agreement as to
the relative titers of the different vectors in the different
sets and assays, in subsequent tables, single represen-
tative titration sets are shown.
The ST1EGFP stock had titers of 4.3 to 5.8 3 105
unit/ml. This vector is 8 kb in length, with a 3.6-kb dele-
tion in gag, with a 1.4-kb IRES-EGFP cassette inserted
into the second rev exon. To test if a vector with a smaller
genome would give higher titers, ST1.2EGFP (6.8 kb) was
prepared, which contained an additional deletion of 1.2
kb in env; however, this vector gave lower titers than
ST1EGFP (four- to sevenfold lower). Vector ST3EGFP
was similar to ST1.2EGFP, except that gag-pol was ren-
dered defective by insertion of two consecutive stop
codons at positions 1074 and 1077 instead of by deletion
microscopy of CMMT-CD4 cells infected with an undiluted stock of
, and pS-env. (A) EGFP fluorescence at 96-h postinfection. (B) The same
sence of both fluorescent and nonfluorescing cells. (C) Same field as
d CMMT-CD4 cells. Note the complete absence of EGFP fluorescence.
e field as (D) and (E) under light microscopy only.rescent
VODC
the pre(genome length 10.4 kb). Despite the longer genome






























159SIV VECTORSthan ST1.2EGFP). The lowest vector titers were obtained
from vectors containing an IRES sequence near the 59
end of the genome. These included the vectors
ST4EGFP, STX2EGFP, and ST3X2EGFP.
The vector that gave the highest titer stocks was
V1EGFP. V1EGFP contains a 1.2-kb deletion in env, a
234-bp deletion in vif, two consecutive stop codons
(codons 8 and 9) in gag, and substitution of the EGFP
gene for a deletion in nef (genome length 9.4 kb).
V1IRES-EGFP is identical to V1EGFP, except for the pres-
ence of an IRES at the beginning of the EGFP gene.
V1IRES-EGFP gave stocks of somewhat lower titer than
V1EGFP (1.7- to 1.9-fold lower).
Parameters affecting the helper plasmids. We also
investigated the effects of different sequences and orga-
nizations in the helper plasmids on the efficiencies of
vector production. Four different gag-pol expression
plasmids were examined: pUpSVO, pUpSVODC, pNK3,
and pSIVSVODC. The organizations of these helper plas-
mids are shown in Fig. 4. pUpSVO is derived from a
molecular clone of SIVmac239 and contains a 1.2-kb
deletion in env, a 511-bp deletion in nef, and a heterol-
ogous M-MuLV LTR at the 39 end. pUpSVODC was de-
rived from pUpSVO by deletion of the putative packaging
sequence, C (Rizvi and Panganiban, 1993). pNK3 is de-
scribed above (see Fig. 1), and pSIVSVODC is a plasmid
ersion of a complete SIVmac239 provirus from which
he C sequences have been deleted. All gag-pol helper
TABLE 3
Titers of Different Vectorsa
Vector
Calculated titerb
Set 1c Set 2c
ST1EGFP 4.25 3 105 (60.235) 5.83 3 105 (62.6)
T1.2 EGFP 5.92 3 104 (60.45) 1.31 3 105 (60.91)
T3EGFP 3.24 3 105 (60.18) 3.37 3 105 (60.46)
T4EGFP 1.50 3 103 (60.17) 1.34 3 103 (60.34)
TX2EGFP 1.00 3 103 (60) 8.34 3 102 (61.7)
T3X2EGFP 1.72 3 104 (60.32) 1.23 3 104 (60.37)
1EGFP 5.44 3 105 (60.31) 6.58 3 105 (61.7)
1IRES-EGFP 2.82 3 105 (60.14) 3.87 3 105 (61.5)
a Infection of CMMT-CD41 cells with viral vectors produced by
ransfection of 293T cells with different vector plasmids, the gag-pol
elper plasmid pUpSVODC, and the env helper plasmid pS-env under
tandard conditions. Used were 2 3 106 CMMT-CD41 for infection with
ml of each vector supernatant. Prior experiments had determined that
these amounts of vector and CMMT-CD41 cells were in the linear
range for titration. EGFP positive cells were scored by fluorescent
microscopy 96 h after initiation of infection.
b Calculated titers are in green forming units per milliliter (GFU/ml).
c Two sets of vector stocks were prepared; for each set, all vectors
were prepared at the same time. Aliquots of the stocks were frozen at
280°C. Each set was then titered twice at two separate times, and the
average vector titers and the ranges are shown.lasmids contained the SV40 origin of replication (SVO)
or amplification and high expression in 293T cells. As an
p
finitial test, these helper plasmids were transfected into
293T cells by themselves, and the cells were examined
for expression of gag and pol proteins by Western blot
analysis using a polyclonal antibody raised against the
SIVmac239 (Fig. 5). The results indicated efficient ex-
pression from pUpSVO and pUpSVODC (as measured by
27 CA protein), while there was significantly less effi-
ient expression from pNK3. pSIVSVODC had levels of
viral protein expression equivalent to pSIVSVO (a full-
length proviral clone of SIVmac239). These four helper
plasmids were each cotransfected into 293T cells with
the env expression plasmid pS-env and the vector plas-
mid pV1EGFPSVO. As shown in Table 4, the pUpSVO
helper plasmid gave V1EGFP titers of 1.37 3 105 unit/ml,
hile deletion of the C sequences from the plasmid
ielded a stock with higher titer (4.93 3 105 unit/ml,
approximately threefold higher). The pNK3 helper plas-
mid was relatively ineffective, giving a vector stock with
a titer of 5.3 3 103 unit/ml (on several repeat transfection
nd infections). Surprisingly, pSIVSVODC, which was
inimally changed from an infectious SIVmac239 provi-
us, produced no detectable infectious vector particles.
n another experiment, a low titer of vector (ca. 10 GFU/
l) was obtained with pSIVSVODC as the helper.
We next investigated the env helper plasmids. As
hown in Fig. 6, we have used two env helper plasmids,
NK4 and pS-env. These two helper plasmids are similar
n that the env sequences for both are derived from
FIG. 4. Gag-pol helper plasmids. Schematic diagrams of the SIV-
mac239-based gag-pol helper plasmids pUpSVO, pUpSVODC,
pSIVSVODC, and pNK3. (A) pUpSVO, contains a deletion in env and nef
nd a heterologous MLV-39LTR. (B) pUpSVODC, similar to pUpSVO, but
ith an additional deletion in the packaging sequence (C). (C)
SIVSVODC, contains the whole SIVmac239 proviral sequence except



















160 KIM ET AL.SIVmac239, and expression is driven by the CMV imme-
diate early promoter. However, the polyadenylation se-
quences for pNK4 are derived from the bovine growth
FIG. 5. Viral protein synthesis by helper plasmids. 293T cells were
transfected individually with different gag-pol helper plasmids
(pUpSVODC, pUpSVO, pNK3, and pSIVSVODC) or env helper plasmids
(pSIVSVODC, pS-env, and pNK4). For a control, cells were transfected
with pSIVSVO, a plasmid with a complete SIV provirus that produces
infectious SIVmac239. Cell extracts were prepared and then subjected
to SDS–PAGE and Western blotting with serum from an SIV-infected
rhesus macaque that reacts with both env and gag proteins. Two
different gels of the same extracts were run to allow optimal visualiza-
tion of the envelope gp120/160 proteins (indicative of env gene expres-
sion) and the gag CA (p27) protein (indicative of gag [and presumably
gag-pol] expression). As shown in the pSIVSVO lane, the antiserum
reacted with gp160 (SU-TM) and gp120 (SU) and also with p27 (CA). The
gag-pol helper plasmids pUpSVO, pUpSVODC, and pSIVSVODC
showed the presence of cleaved p27 protein; pUpSVO also showed
higher molecular weight proteins in the gag region, suggestive of
precursor polyproteins. The env helper plasmid pS-env showed syn-
thesis of gp120/160; however, pNK4 showed substantially lower
amounts of env protein (visible at longer exposures). The locations of
gp160, gp120, and p27 are indicated.
TABLE 4
Titers of V1EGFP Obtained with Different gag-pol Helper Plasmidsa
Gag-pol helper Calculated titerb
pNK3 5.33 3 103
pUpSVO 1.37 3 105
pUpSVODC 4.93 3 105
pSIVSVODC 0
a Titers on CMMT-CD41 cells of V1EGFP produced by transfection of
93T cells with the pV1EGFPSVO vector plasmid, pS-env, and the
ifferent gag-pol helper plasmids under standard conditions. Infections
ere carried out as described in Table 3.
b Titers are in green forming units per milliliter (GFU/ml).hormone gene. Western blot analysis using polyclonal
antibodies against the SIVmac239 envelope indicated
that there was poor expression of the envelope proteins
from pNK4, whereas the pS-env construct was efficient
at expressing the viral envelope proteins (Fig. 5). When
these two env expression plasmids were tested in par-
allel cotransfections with pV1EGFPSVO and pUpSVODC,
S-env was approximately 10-fold more effective as a
elper than pNK4 (Table 5). Two other versions of pS-env
ere generated, in which the viral sequences were de-
ived from SIVmac316 (M-tropic) or SIVmac1A11 (dual-
ropic)–p316env and p1A11 env. p316env consistently
ave titers equivalent to pS-env, while p1A11 gave some-
hat lower titers (Table 5).
Finally, we tested the effect of the SV40 origin of
eplication on the vector and helper plasmids. While
ther investigators have demonstrated that inclusion of
he SVO on plasmids leads to highly efficient expression
n cells that contain SV40 large T antigen (such as 293T
ells), we explicitly tested the importance of the SVO in
FIG. 6. Envelope helper plasmids. Schematic diagrams of the two
envelope helper plasmids pS-env and pNK4. (A) pS-env, contains the
CMV immediate early promoter and the 39SIV LTR and expresses the
SIVmac239 env, tat, rev, and nef. (B) pNK4, contains the CMV immedi-
ate early promoter and the bovine growth hormone poly(A) and ex-
presses env, tat, and rev.
TABLE 5
V1EGFP Titers with Different Envelope Helper Plasmidsa
Envelope helperb Calculated titerc
pNK4 5.07 3 104
pS-env 4.93 3 105
p1A11env 8.96 3 104
p316env 5.82 3 105
a Titers on CMMT-CD41 cells of V1EGFP produced by transfection of
93T cells with pV1EGFPSVO, pUpSVODC gag-pol helper plasmid, and
ifferent envelope helper plasmids. Infection conditions were as in
able 3.
b pNK3 and pS-env contain envelope sequences from T-lymphotropic
SIVmac239. p1A11env contains envelope sequences from the dual-
tropic SIVmac1A11. p316env contains the macrophage tropic SIV-
mac316 envelope sequences.





























161SIV VECTORSour SIV-based vector system. We generated pairs of
vector plasmids lacking or containing SVO (e.g.,
pV1EGFP vs. pV1EGFPSVO) and also similar pairs of the
gag-pol helper plasmids. Different combinations of these
plasmids were then cotransfected into 293T cells, and
the titers of the resulting vectors were measured by
infection on CMMT-CD4 cells as shown in Table 6. We
consistently found 2- to 3-fold higher titers with incuba-
tion of transfected cells at 32 vs. 37°C (data not shown).
This was expected, since the large T antigen in 293T
cells is temperature sensitive (optimally functional at
32°C). The results indicated that the presence of the SVO
on the vector plasmid resulted in 10-fold higher titers of
vector. The presence or absence of the SVO on the pUp
helper plasmid had little effect on vector titer, but on the
pUpDC plasmid, addition of the SVO led to approxi-
mately 2-fold higher levels of vector infectivity. Thus for
the most efficient vector–helper plasmid combination,
the presence of the SVO had a substantial effect on
vector titer (ca. 10-fold).
Chloroquine treatment of transfected 293T cells. Other
nvestigators have shown that addition of chloroquine
uring plasmid transfections can increase the efficiency
f expression. Therefore we tested if addition of chloro-
uine to the transfected 293T cells could result in higher
iters of vector. Cells were treated with 50 mM chloro-
uine 30 min before cotransfections with vector and
elper plasmids and the transfections were also carried
ut in the presence of medium containing chloroquine.
welve hours posttransfection the cells were switched to
edium lacking chloroquine, and vector supernatants
ere collected 84 h thereafter. Infectivity assays indi-
ated that chloroquine treatment increased the resulting
ector titers by two- to threefold (not shown). Using the
ptimal vector–helper plasmid combination and chloro-
TABLE 6
Effect of the SV40 ORI on Vector Titer
Vector Vector plasmid Gag-pol plasmid Calculated titer
1. ST1EGFP pST1EGFP pUpSVODC 2.93 3 104
2. ST1EGFP pST1EGFPSVO pUpSVODC 3.26 3 105
3. V1EGFP pV1EGFP pUpSVODC 3.93 3 104
4. V1EGFP pV1EGFPSVO pUpSVODC 4.93 3 105
5. V1EGFP pV1EGFPSVO pUpDC 2.31 3 105
6. V1EGFP pV1EGFPSVO pUpSVO 1.37 3 105
7. V1EGFP pV1EGFPSVO pUp 1.38 3 105
a Titers on CMMT-CD41 cells of vector stocks produced by trans-
fection of 293T cells with different vector plasmids with or without an
SVO, pUpSVODC gag-pol helper plasmid, and the pS-env env plasmid
(1–4). V1EGFP vector titers produced by 293T transfection with different
gag-pol helper constructs, the pV1EGFPSVO vector plasmid, and the
pS-env env plasmid (5–7). Infection conditions were as in Table 3.
b Titers are in green forming units per milliliter (GFU/ml).uine treatment of cells, V1EGFP vector stocks with titers
p to 5 3 106 GFU/ml were obtained.Elimination of replication-competent recombinants. A
major concern in design of retroviral vectors is the ap-
pearance of replication-competent recombinants (RCRs).
In the case of the SIV-based vectors described here, this
was a particular issue for vectors generated with the
gag-pol helper plasmid pUpSVO and the env helper plas-
mid pS-env, since a single recombination between these
two plasmids could result in a complete SIVmac239
provirus. A V1EGFP stock generated by cotransfection
with these two helper plasmids was tested for the pres-
ence of RCRs by end-point dilution onto susceptible
CEMX174 cells followed by serial passage of the dilu-
tions and assays of supernatants for reverse transcrip-
tase activity. The results indicated the presence of rep-
lication-competent SIV at a concentration of 102 to 103
IU/ml. The same vector stock had a vector concentration
of 1.4 3 105 unit/ml. Thus RCRs were present at the 1022
to 1023 level. We next tested if elimination of the C
equences from the pUpSVO plasmid would reduce this
roblem. In theory elimination of these sequences would
ave two effects: first, a single recombination event
ould not yield a replication-defective provirus; second,
he pUpSVO transcript would not be packaged into ret-
oviral particles. When we generated V1EGFP stocks
sing the pUpSVODC and pS-env helper plasmids, we
ere unable to detect RCRs in the resulting vector stock
,5 IU/ml). Thus elimination of the C site was effective in
ubstantially reducing or eliminating RCRs from the vec-
or stocks.
As a more sensitive test for RCRs, serial dilutions of a
1EGFP vector stock using the pUpSVODc and pSenv
helper plasmids were infected into CEMX174 cells, and
the infected cells were serially passaged. At the fifth
passage, DNA was extracted from the cells and assayed
by PCR for the presence of SIV envelope sequences that
were deleted in V1EGFP. The presence of these se-
quences would be indicative of RCRs. None of the serial
dilutions resulted in RCR-positive cultures as measured
by this assay. The results were consistent with the lack
of RCRs as assayed by RT assays.
Efficiency of reporter expression. As described above,
we generated several SIV-based vectors that express
EGFP from different locations within the SIV genome, in
some cases under control of an IRES. To compare the
relative efficiencies of EGFP expression from the differ-
ent vectors, CEMX174 cells were infected with each of
the vectors and monitored for intensity of EGFP expres-
sion by flow cytometry 3 days postinfection. The results
are shown in Fig. 7. The highest intensity of fluorescence
resulted from the ST1EGFP vector that expresses EGFP
under control of an IRES from an early mRNA. Adding a
deletion in env (ST1.2EGFP) somewhat reduced intensity
of EGFP expression. Placement of the IRES-EGFP cas-
sette into the nef region (V1IRES-EGFP) also gave some-
what lower fluorescence than ST1EGFP. In fact, the IRES

















162 KIM ET AL.in the nef coding region, since the intensities for V1EGFP
and V1IRES-EGFP were equivalent. Somewhat surpris-
ingly, vectors containing two IRES-EGFP cassettes did
not show higher efficiencies of EGFP expression than
those with one IRES-EGFP cassette; indeed in general
they expressed EGFP less efficiently.
DISCUSSION
In this report, we have investigated several parame-
ters involved in SIVmac-based vector production. The
first issue was the choice of reporter proteins. We found
that the b-galactosidase protein, while having the advan-
age of a sensitive enzymatic assay for detection, had the
mportant disadvantage of transfer of free b-gal protein
uring vector infections. While this problem could be
ircumvented in some in vitro infections by omitting
EAE–dextran, peripheral blood mononuclear cells
ould take up soluble b-gal in the absence of DEAE–
extran (most likely by phagocytosis) and the X-gal stain-
ng pattern of these cells was indistinguishable from
enuine NK1-infected cells (S. Kim and H. Fan, not
hown). We attempted to reduce the level of contaminat-
ng b-gal protein from vector supernatant by ultracentrif-
ugation, spin dialysis, immunoadsorption, and construc-
tion of a tetracycline-inducible vector system. Attempts to
physically separate b-gal proteins from vector particles
FIG. 7. Fluorescence intensities of different EGFP vectors. Flow cytom
96 h after initiation of infection, and the mean fluorescence intensities
pUpSVODC and the envelope helper plasmid pS-env. The mean fluor
ntensity values for the other vectors are shown as a percentage of thwere largely unsuccessful, perhaps due to two factors:
the large size of the b-gal protein (480 kDa as a tetramer)nd the substantial reductions in titer during concentra-
ion. Attempts to construct a replication-defective SIV-
ased vector that expressed b-gal under an inducible
promoter (tet-off system; Paulus et al., 1996, 1997; Yu et
al., 1996) were partially successful. We were able to
produce vector stocks that contained minimal levels of
b-gal protein, but the titers were 3 to 4 logs lower than
titers from comparable vectors lacking the tet-off pro-
moter (e.g., ST1EGFP; Kim and Fan, unpublished results).
Unlike the b-gal, vectors expressing EGFP did not
have the same problem with uptake of reporter protein.
While soluble EGFP was presumably present in the vec-
tor stocks, we did not find any EGFP signal in infected
cells that was resistant to inhibition by the reverse tran-
scriptase inhibitor PMPA. The most likely reason is that
threshold levels of intracellular EGFP are required for
detectable fluorescence (30 nM for HeLa cells, Clontech,
Palo Alto, CA). The EGFP detected in the target cells
resulted from de novo expression since the EGFP was
sensitive to inhibition by PMPA, sensitive to inhibition by
heat inactivation of the virus (therefore not resulting from
carryover of vector plasmid DNA), and exhibited a time-
dependent increase in expression.
Next we explored parameters affecting efficient vector
expression. We found that the ST1EGFP vector whose
genomic length more closely resembled wild-type SIV
s performed on CEMX174 cells infected with the different EGFP vectors
etermined. All vectors were packaged with the gag-pol helper plasmid
e intensity of cells infected with ST1EGFP was set at 100%, and the
GFP fluorescence.etry wa
were dhad four- to sevenfold higher titers than ST1.2EGFP (6.8




















































163SIV VECTORSproduced vectors at levels comparable to ST1EGFP. The
vectors also allowed us to compare different methods of
rendering the vector plasmid replication-defective: dele-
tion of gag-pol sequences versus introduction of stop
codons in gag. We found 2.5- to fivefold higher titers with
ST3EGFP than ST1.2EGFP (Table 2), suggesting that the
59 gag sequences may contribute to optimal vector titers.
The possible role of gag-pol sequences in HIV produc-
tion has been described by Parolin et al. (1994). For HIV,
nclusion of 653 nucleotides containing the 59 portion of
he gag gene improved vector production.
The use of an IRES for heterologous gene expression
n retroviral vector systems has the advantage that an
RES-gene cassette can be placed anywhere in an exon
nd be efficiently expressed (Kim et al., 1998). We found
hat for SIV-based vectors, the position of the IRES cas-
ette greatly affected the titer. In particular, placement of
he IRES-EGFP cassette near the 59 end of the vector
enome resulted in a substantial decrease in titer com-
ared to when the IRES-EGFP was further away from the
9 end (e.g., ST4EGFP vs. ST1.2EGFP, Fig. 3 and Table 3).
ne possible reason could be that the tertiary structure
f the IRES may hinder the RNA interactions necessary
or packaging or dimer formation (Clever and Parslow,
997; Laughrea et al., 1997; McCann and Lever, 1997).
ntroduction of a second IRES-EGFP cassette in the gag
egion resulted in drastic decreases in titers (STX2EGFP
nd ST3X2EGFP, Table 3). Placing an IRES toward the 39
nd of the vector genome (V1EGFP vs. V1IRES-EGFP, Fig.
) resulted in relatively little effect on vector titer. Use of
n IRES-EGFP cassette showed minimal benefits on the
evels of EGFP expression; vectors with multiple IRES-
GFP cassettes actually showed less expression.
With regard to the helper gag-pol helper plasmids,
eletion of the psi (C) packaging sequences also af-
ected vector titers. We initially introduced the C deletion
nto these plasmids to decrease the formation of repli-
ation-competent recombinants, but also found a ca.
hreefold increase in titer (Figs. 4A and 4B, Table 4). One
ossible explanation was that with the introduction of the
deletion, there was decreased packaging of gag-pol
elper plasmid RNA and a concomitant increase in pack-
ging of vector RNA. Of two other gag-pol expression
lasmids, the low vector titers obtained with pNK3 might
eflect inefficient use of the bovine growth hormone
oly(A) signal, or the lack of 39 SIV sequences (Fig. 4 and
able 4). The other gag-pol helper plasmid, SIVSVODC,
as expected to provide optimal titers because it had
inimal changes relative to SIVmac genomic se-
uences, and it was effective in the expression of the
ag and envelope proteins (Fig. 5). However, SIVSVODC
as the least efficient gag-pol helper plasmid (Table 4).
ne potential explanation could be that processing of
he gag polyprotein seemed delayed (Fig. 5), which might
ndicate inefficient particle formation or proteolytic cleav-
ge.For the envelope helper plasmids, the heterologous
ovine hormone poly(A) sequences may have been less
fficient than those of the SIV LTR (Table 5).
The presence of the SVO on the vector plasmids in-
reased vector titers ca. 10-fold (e.g., pV1EGFP vs.
V1EGFPSVO), as expected (Table 6). On the other hand,
he presence of the SVO on the gag-pol helper plasmid
ad less effect (e.g., pUpDC vs. pUpSVODC), which
might suggest that the limiting factor in viral particle
formation is vector genomic RNA.
Cotransfection of 293T cells in the presence of chlo-
roquine increased vector titers two- to threefold. To ex-
ploit chloroquine’s beneficial effect on lysosomal degra-
dation without adversely affecting vector infectivity, we
exposed the transfection reactions to chloroquine, allow-
ing for optimal amplification of the vector, gag-pol helper,
and env plasmids and then switched the cultures to
media lacking chloroquine. The resulting vectors were
able to infect the same range of cells as those produced
in the absence of chloroquine, including rhesus ma-
caque PBMCs, rhesus macrophages, CEMX174 cells,
SupT1 cells, CMMT-CD4 cells, and Molt4–Clone8 cells
(Kim and Fan, unpublished results).
We decreased the level of RCRs in these vectors to
undetectable levels (,5 IU/ml) by deleting C from the
gag-pol helper plasmid. The presence of the C deletion
in pUpSVO would require three recombination events to
generate an RCR. First, the gag-pol helper plasmid would
have to recombine twice over a small distance (132 bp)
with the pV1EGFPSVO vector plasmid to recover func-
tional C sequences, followed by recombination with the
env helper plasmid to recover the native 39 sequences.
For some applications, the likelihood of RCR formation
could be reduced further by substitution of a heterolo-
gous viral envelope as described by others (Akkina et al.,
1996; Chang et al., 1999; Douglas et al., 1999; Gallardo et
al., 1997; Kafri et al., 1999; Li et al., 1998; Mochizuki et al.,
1998).
In summary, systematic variation of SIVmac-based
vector design allowed us to optimize efficiency of vector
expression plasmids and helper plasmids and to reduce
the level of RCRs. While in many cases the differences by
varying one parameter were relatively small (two- to
fivefold), combining the optimal plasmids ultimately re-
sulted in production of replication-defective, helper-free
vector stocks of quite high titer (.106/ml). Production of
SIV-based helper-free stocks of these titers, without use
of a heterologous viral envelope, has not been previously
reported.
MATERIALS AND METHODS
Construction of vector plasmids
pNK1. A 3.6-kb deletion was made in pBRmac239SpSp59
(a plasmid containing the 59 half of the proviral clone pSIV-


































164 KIM ET AL.with BamHI (position 1849) and BglII (position 5441) and
replaced with a 3.7-kb BamHI–BamHI DNA fragment con-
taining the Escherichia coli b-galactosidase gene immedi-
tely downstream of the encephalomyocarditis (EMC) virus
nternal ribosome entry site (Jang et al., 1989). The 39 half of
SIVmac239 was introduced as a SphI (6450) to EcoRI
10279) fragment (from pBRmac239SpE9, provided by Dr.
onald Desrosiers) to generate pNK1.
pNK2. A 3.6-kb deletion was made in pBRmac239SpSp59
y digestion with BamHI (position 1849) and BglII (position
441) and religated to generate pBRmac239SpSp59Dgag-
ol. The 39 half of pSIVmac239 was introduced as a SphI
6450) to EcoRI (10279) fragment (from pBRmac239SpE9) to
enerate pSIVmac239Dgag-pol. Next, a 3.6-kb BamHI–
amHI IRES-b-gal cassette was inserted into the BglII site
(9118) of pSIVmac239Dgag-pol to generate pNK2. The ori-
entation of the IRES-b-gal insert was determined by restric-
ion enzyme digests.
pST1EGFP and pST1EGFPSVO. First, a 440-bp DNA
ragment containing the minimal simian virus 40
SV40) origin of replication (ORI) was inserted into the
coRI site (10279) of pSIVmac239Dgag-pol to generate
SIVSVODgag-pol. Next, a 1.4-kb BamHI–BamHI DNA
ragment containing the Aquaria victoria jellyfish-en-
anced green fluorescent protein (Clontech) down-
tream of the EMC IRES was inserted into the BglII site
9118) of pSIVSVODgag-pol to generate pST1EGFPSVO.
he SV40 ORI was removed from pST1EGFPSVO by
coRI digestion, which released a 440-bp fragment con-
aining the SV40 ORI to generate pST1EGFP.
pV1EGFP, pV1EGFPSVO, and pV1IRES-EGFPSVO. A
deletion in env (from 6603 to 7758) was introduced to
pSIVDNU, a proviral clone of SIVmac239 containing de-
letions in nef and the U3 region (Gundlach et al., 1997), to
generate pSIVDNUDenv. The 813-bp fragment encoding
the 700-bp EGFP gene was cloned in place of nef. Ex-
pression of SIVgag-pol was blocked by introducing two
stop codons at codons 8 and 9 of gag by PCR. In
addition, the vif gene was replaced by a vif gene con-
aining a deletion (Gibbs et al., 1994), kindly provided by
r. Ronald Desrosiers through the AIDS Research and
eference Reagent Program, resulting in pV1EGFP. The
40-bp fragment containing the SV40 ORI was cloned
nto the EcoRI site (10279) of pV1EGFP to produce
pV1EGFPSVO. For pV1IRES-EGFPSVO, the EGFP gene of
pV1EGFPSVO was replaced with a 1.4-kb DNA fragment
containing an IRES-EGFP cassette.
pSTX2EGFPSVO. An amount of 3.6 kb of gag-pol se-
quences was removed from pSIVmac239SpSp59 by di-
gestion with BamHI (1849) and BglII (5441) and replaced
with a 1.4-kb IRES-EGFP BamHI–BamHI DNA cassette.
Subsequently, this plasmid was digested with AvaI (1502
and 5750) to release a 2.1-kb fragment containing the
IRES-EGFP insert. This 2.1-kb fragment was introduced
into pST1EGFPSVO, replacing the corresponding AvaI–AvaI sequences, to produce pSTX2EGFPSVO. This vector
is designed to have two IRES-EGFP inserts.
pST3EGFPSVO. 39 end sequences of pV1EGFPSVO
from ClaI (8073) to AatII (4284 of pBR322) were replaced
with the corresponding ClaI–AatII sequences from
pST1EGFPSVO to produce pST3EGFPSVO.
pST3X2EGFPSVO. Sequences from BamHI (1849) to
BglII (5441) were removed from pST3EGFPSVO by re-
striction enzyme digestion and replaced with a 1.4-kb
BamHI–BamHI DNA fragment containing an IRES-EGFP
cassette to generate pST3X2EGFPSVO.
pST1.2EGFPSVO. The 39 end of pST1EGFPSVO from
SphI (6450) to AatII (4284 of pBR322) were replaced with
the corresponding 39 sequences of pST3EGFPSVO.
pST4EGFPSVO. pSTX2EGFPSVO was first digested
with ClaI (position 8073) and Aat II (position 12000). The
resulting 8-kb fragment encompassing the 59 LTR and an
IRES-EGFP cassette in place of gag and pol was ligated
to a 2.6-kb fragment derived from the construct pSIVSVO.
The 2.6-kb fragment was released as a ClaI (position
8073) and Aat II (position 10679) fragment and contains
the 39 LTR and the SV40 ori.
Construction of gag-pol expression plasmids
pNK3. First, the rev response element (RRE) was in-
troduced into pCDNA3 (Invitrogen, Carlsbad, CA) as a
laI (converted to a blunt end) to EcoRI fragment derived
rom pBRmac239(E)D39LTR (a plasmid containing only
he 59 half of SIVmac239, provided by Dr. Ronald Desro-
iers). The fragment was inserted into the BamHI (con-
verted to blunt end) and EcoRI site on the polylinker of
pCDNA3. Then, the sequences from NdeI (290) to SphI
6450) that encode gag-pol but lack C (from
p59SIVmac239DC, see construction of pSIVSVODC be-
low) were placed immediately downstream of pCDNA3’s
cytomegalovirus (CMV) promoter as a HindIII–HindIII
fragment (after conversion of the ends to HindIII sites)
into the HindIII site of pCDNA3’s polylinker.
pSIVSVODC. The putative packaging signal C (Rizvi and
Panganiban, 1993) was deleted from pBRmac239SpSp59 by
digestion with NarI (824) and KpnI (941), blunt-end filling by
Klenow polymerase, and then ligating by T4-ligase to pro-
duce p59SIVmac239DC. The 39 SIVmac239 sequences
were introduced as a BamHI (1849) to AatII (4284 of
pBR322) fragment to produce pSIVDC. The SV40 ORI was
added at the EcoRI site (10279) as a 440-bp EcoRI–EcoRI
fragment, producing pSIVSVODC.
pUpSVODC and pUpDC. Using a PCR approach, a
deletion in env from 6347 to 7502 was introduced into
pSIVDNU. The 39LTR of this plasmid, designated
pSIVDenvDNU, was then replaced by a PCR-generated
fragment containing the MLV-LTR with its polyadenyla-
tion signal, using the XbaI and EcoRI sites resulting in
pBRmac239Denv2pAd (Sgp, Schnell et al., 2000). The






































165SIV VECTORSsite (10279) of Sgp to generate pUpSVO. To construct
pUpSVODC, a 117-bp deletion (NarI to KpnI) in the puta-
tive packaging sequence was made by restriction en-
zyme digestion. The SV40 ORI was removed from
pUpSVODC by digestion with EcoRI to produce pUpDC.
onstruction of envelope expression plasmids
pS-env. A fragment comprising nucleotides 6450 (SphI)
o 10280 of the SIVmac239 proviral clone and cellular
lanking regions was cloned into the HindII–EcoRI site of
CDNA-I-Amp (Invitrogen) resulting in pS-env.
pNK4. First, the KpnI site (5775) of SIVmac239 was
onverted to a BamHI site by restriction digest with
sp718 followed by ligation of a BamHI linker. Se-
uences from the newly introduced BamHI (5775) to
coRI (9751) of SIVmac239 that include those encoding
nv, tat, and rev were introduced into the BamHI and
EcoRI site of pCDNA3 that carries the bovine growth
ormone poly(A) signal (Invitrogen).
ell lines
293T cells, a human embryonic kidney cell line that
xpresses the simian virus 40 large T antigen (Li and
elly, 1984), were obtained from the American Type Tis-
ue Culture Collection (Rockville, MD). The cells were
aintained in Dulbecco’s modified Eagle’s medium
DMEM) supplemented with 10% fetal bovine serum
FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, and
00 mg/ml L-glutamine. CMMT-CD4 cells (a rhesus ma-
caque mammary tumor cell line that expresses human
CD4 (Chackerian et al., 1995)) were maintained in DMEM
supplemented with 10% FBS, 100 U/ml penicillin, 100
mg/ml streptomycin, 300 mg/ml glutamine, and 0.2 mg/ml
geneticin (G418, at an active concentration of 700 mg/
mg). sMAGI cells were maintained in DMEM with 10%
FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 300
mg/ml glutamine, 0.2 mg/ml geneticin, and 50 U/ml hy-
gromycin (Calbiochem, La Jolla, CA). CEMX174 (a human
T-cell/B-cell hybrid cell line; AIDS Research and Refer-
ence Reagent Program, NIH) was maintained in RPMI
1640 with 10% 2mM L-glutamine.
Vector production
Vector stocks were made by transient transfections of
293T cells. Briefly, 2 3 105 293T cells were plated 2 days
prior to transfection in 6-cm tissue culture dishes. The
plates were refed 2 h prior to transfection with 5 ml of
fresh DMEM with 10% FBS. Transfections were per-
formed by the calcium phosphate method using the Cal-
phos Maximizer transfection kit (Clontech). A total of 15
mg of plasmid DNA (5 mg of each plasmid: pV1EGFPSVO,
pUpSVODC, and an envelope expression plasmid) were
used and transfection reactions were incubated at 37°C,
5% CO2. Plates were refed with half volume (2.5 ml) of
edia 12 h posttransfection and incubated at 32°C, 5%
a
bO2. Twenty-four hours after refeeding, vector superna-
ants were collected, filter clarified through a 0.45-mm
filter, and then stored frozen at 2140°C.
Titration of vector stocks
Onto 12-well plates, 5 3 104 CMMT-CD4 cells were
plated 24 h prior to infection with 2 ml of media. Infec-
tions were carried out by removing media from the wells,
adding 295 ml of fresh media and 15 mg/ml DEAE–
extran, and then adding 5 ml of diluted vector stock. Two
hours poststart of infection, 2 ml of fresh media was
added to each well. Four days later, the CMMT-CD4 cells
were microscopically scanned for EGFP expression us-
ing a fluorescent microscope with a FITC filter designed
for optimal EGFP detection (Chroma Technology, Brattle-
boro, VT). Titers of each vector stock were calculated by
taking the total number of EGFP-positive colonies, mul-
tiplying that number by 200 (to correct for volume of
supernatant used), and then multiplying by the dilution
factor. Titers are defined as green forming units per
milliliter (GFU/ml).
Infections
Onto 12-well plates, 5 3 104 sMAGI cells were plated
24 h prior to infection with 2 ml of media. Infections were
carried out by removing media from the wells, adding
295 ml of fresh media, 15 mg/ml DEAE–dextran, and then
dding 5 ml of diluted vector stock. Two hours poststart
of infection, 2 ml of fresh media was added to each well.
Four days later, the cells were either microscopically
scanned for EGFP expression or fixed with 1% parafor-
maldehyde and 2% glutaraldehyde for 5 min, washed
with phosphate buffered saline 3 times, and then X-gal
stained for 50 min.
For CEMX174 cells, 1 3 106 cells were plated into
12-well plates in 200 ml of fresh media. Five hundred
icroliters of vector supernatant was added to each well
nd incubated at 37°C. Five hours later, 2 ml of fresh
edia was added to each well. Four days later, the cells
ere screened for EGFP expression by fluorescent mi-
roscopy or FACS.
estern blot analysis
293T cells were transfected with 5 mg of the various
ackaging vectors generated (pUpSVODC, pUpSVO,
NK3, pSIVSVODC, pSIVSVO, pS-env, or pNK4) using the
alcium phosphate method described above. The cells
ere washed with PBS 48 h posttransfection and RIPA
ysates were prepared. Whole-cell lysates (20mg/lane)
ere electrophoresed through an 8% sodium dodecyl
ulfate (SDS) polyacryamide gel. Proteins were trans-
erred to a Hybond ECL nitrocellulose membrane (Amer-
ham). All incubations were performed at room temper-
ture, and membranes were washed 3 times for 10 min












166 KIM ET AL.with 5% skim milk in PBS–0.4% Tween 20 for 1 h and then
incubated with a 1:20,000 dilution of sera from an SIV-
mac239-infected rhesus macaque in 5% skim milk in
PBS–0.05% Tween 20 for 1 h. Dilutions of secondary
antibodies and detection were performed as described
by the manufacturer of the enhanced chemilumines-
cence system (Amersham).
Flow cytometry
For flow cytometry, cultures of infected CEMX174 cells
were pelleted with low-speed centrifugation and resus-
pended in 1 ml PBS. After 30 min at room temperature, cell
suspensions were analyzed by flow cytometry with a Bec-
ton–Dickinson FACScalibur in the analytical mode. EGFP-
positive cells were detected in the green fluorescence
channel. Events from 5000–10,000 cells were recorded.
Characterization of vectors
Reverse transcriptase inhibition assays were per-
formed by preloading CMMT-CD4 cells, CEMX174 cells,
and sMAGI cells with 25 mM 9-(2-phophonylmethoxypro-
yl) adenine (PMPA; Gilead Sciences, Hayward, CA
Srinivas et al., 1993)) 1 h prior to infection with vectors.
ifty microliters of each undiluted vector was used for
nfection. Ninety-six hours after initiation of infection,
MMT-CD4 and CEMX174 cells were screened by fluo-
escent microscopy for EGFP expression. sMAGI cells
ere screened by fluorescent microscopy for EGFP ex-
ression and X-gal-stained for b-gal expression as de-
cribed above. Vector stocks were tested for replication-
ompetent recombinants by long-term infection of
EMX174 cells. Briefly, 1 3 106 CEMX174 cells in 1.5 ml
of media (RPMI 1640 1 11.5% FBS) were infected with
500 ml of serially diluted and undiluted vector stocks in
triplicate. Thrice weekly for 4 weeks, 750 ml of media
were removed. The media removed from the cells were
clarified by low-speed centrifugation and then PEG pre-
cipitated. Virion pellets were resuspended and level of
reverse transcriptase activity assayed using standard
reverse transcriptase activity as previously described
(Spira et al., 1987). Cells were resuspended in the re-
maining 1.25 ml of media and one-half of the cell sus-
pension (0.6 ml) was removed. Cells were refed with 1.3
ml RPMI 1640 containing 11.5% FBS.
Nomenclature. Throughout this report, we have adopted
the following nomenclature to distinguish between vectors
and the plasmids that encode them. In all cases, plasmids
are designated with the prefix “p” (e.g., pV1EGFP), while the
resulting retroviral vectors do not contain the prefix (e.g.,
V1EGFP). In some cases, plasmids contain an SV40 ORI
outside of the vector coding sequences, to allow amplifica-
tion in SV40 T antigen-containing cells such as 293T; these
plasmids contain “SVO” in their names (e.g., pV1EGFPSVO).
All helper plasmids contain the p prefix with or without SVO
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